Guidelines for Dementia Management
All clinicians—including primary care providers—should implement a structured, evidence-based diagnostic evaluation for suspected Alzheimer's disease and related dementias (ADRD), followed by stage-appropriate pharmacologic and non-pharmacologic interventions aimed at maximizing patient-caregiver dyad quality of life. 1
Diagnostic Evaluation
The 2025 Alzheimer's Association guideline provides the most current framework for diagnosis 1. The evaluation process should characterize three key domains:
- Cognitive-functional status: Use validated neuropsychological testing to quantify impairment
- Cognitive-behavioral syndrome: Identify specific symptom patterns (memory-predominant vs. behavioral-predominant)
- Underlying brain disease: Determine etiology through clinical assessment and biomarkers
Neuroimaging and Biomarkers
Structural imaging (CT or MRI) is recommended to exclude other causes and support differential diagnosis 2. Advanced biomarkers including:
- Amyloid PET imaging or CSF amyloid assays for diagnostic uncertainty
- FDG-PET or SPECT for differential diagnosis between dementia subtypes
- DaT scans specifically for suspected Lewy body dementia 2
Pharmacologic Treatment Algorithm
Alzheimer's Disease
For mild-to-moderate AD, initiate a cholinesterase inhibitor (donepezil, rivastigmine, or galantamine) immediately upon diagnosis 3, 4. The evidence is strongest (Grade A) for cognitive, functional, and global outcomes.
Dosing strategy: Titrate to the highest tolerable dose, as efficacy is dose-dependent 5. Specific options:
- Donepezil: 5-10 mg daily (10-23 mg for moderate-severe)
- Rivastigmine: oral 6-12 mg/day or transdermal patch 9.5-13.3 mg/24h
- Galantamine: 16-24 mg daily
For moderate-to-severe AD, add memantine (titrate to 20 mg daily) to the cholinesterase inhibitor 3, 4. Combination therapy provides additive benefit (Grade B evidence).
Lewy Body Dementias (DLB and PDD)
Cholinesterase inhibitors are first-line treatment (Grade A recommendation) 3. Rivastigmine has specific approval for Parkinson's disease dementia 5. Memantine may provide additional benefit 3.
Vascular and Mixed Dementia
Treat mixed dementia (AD + vascular) as Alzheimer's disease with cholinesterase inhibitors 5. Pure vascular dementia lacks convincing evidence for anti-dementia drugs, though cholinesterase inhibitors show benefit in mixed presentations 3.
Frontotemporal Dementia
Do not use cholinesterase inhibitors—they are ineffective and may worsen agitation (Grade A) 3. Consider selective serotonin reuptake inhibitors (SSRIs) for behavioral symptoms only (Grade B) 3.
Critical Monitoring and Continuation Decisions
When to Continue Treatment
Do not discontinue medications solely because dementia severity increases (Grade A) 3. The Canadian guidelines [2-2] provide specific continuation criteria:
Continue cholinesterase inhibitors if:
- Patient shows stabilization or decreased rate of decline
- Neuropsychiatric symptoms (psychosis, agitation) have improved with treatment 2
- Patient tolerates medication without significant adverse effects
When to Consider Discontinuation
Discontinue cholinesterase inhibitors or memantine after >12 months if 2:
- Clinically meaningful worsening over 6 months despite treatment (excluding delirium or acute illness)
- No observed benefit at any point during treatment
- Severe/end-stage dementia with dependence in most basic ADLs
- Intolerable side effects:
- ChEIs: severe nausea, vomiting, weight loss, falls
- Memantine: confusion, dizziness, falls
- Poor medication adherence preventing safety assessment
Critical exception: Do not stop cholinesterase inhibitors during active psychosis, agitation, or aggression unless these symptoms were caused by the medication 2.
Deprescribing Protocol
When discontinuing, taper gradually (Grade B) 2:
- Reduce dose by 50% every 4 weeks
- Continue at starting dose for 4 weeks before complete discontinuation
- Reinitiate immediately if clinically meaningful worsening occurs during taper 2
Mild Cognitive Impairment
Do not prescribe cholinesterase inhibitors or memantine for MCI (Grade A)—they are ineffective 2, 3.
Behavioral and Psychological Symptoms (BPSD)
Prioritize non-pharmacologic interventions first for all behavioral symptoms 6, 7. When medications are necessary:
- Agitation in AD: Citalopram (conditional recommendation) 7; brexpiprazole is FDA-approved specifically for agitation in AD 8
- Psychosis/aggression: Risperidone (conditional recommendation, short-term only due to stroke risk) 7
- Insomnia in AD: Suvorexant is FDA-approved 8
- Psychosis in AD: Pimavanserin shows efficacy 7
Non-Pharmacologic Interventions
Implement structured non-pharmacologic strategies as core therapy, not adjuncts 9:
- Cognitive stimulation therapy: Structured group activities
- Physical activity programs: Regular aerobic and resistance exercise
- Caregiver education and support programs: Reduce burden and improve outcomes
- Environmental modifications: For safety and behavioral management
- Mediterranean diet: May slow cognitive decline 4
Case management is recommended to coordinate care delivery and address social aspects (Grade B) 2.
Common Pitfalls
- Delaying diagnosis disclosure: The 2025 guideline emphasizes structured disclosure as part of quality care 1
- Stopping medications in advanced disease: Continue if patient previously benefited, especially for behavioral control 2
- Using cholinesterase inhibitors in frontotemporal dementia: This worsens symptoms 3
- Treating MCI with anti-dementia drugs: No evidence of benefit 2
- Inadequate monitoring for amyloid-related imaging abnormalities (ARIA): Required for new anti-amyloid therapies 9, 8
Emerging Disease-Modifying Therapies
Lecanemab and donanemab are FDA-approved anti-amyloid monoclonal antibodies for early AD (2023-2024) 8. These require: